To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action. This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm. To view information about this, please visit the FAQ. If you have any further questions, please contact us.
A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
Provider Data DescriptionThis dataset contains patient-reported acute toxicity and health-related quality of life (QOL) data from trial NCT01672892 to reproduce the results in PubMed ID=29989857.
SponsorRadiation Therapy Oncology Group
Data ProviderNational Cancer Institute
Partial set or SubsetN/A
Patients in dataset289
# of Patients Control0
# of Patients ExperimentalNA
CDISC StandardNCI standard
Clinical Trials.gov Information
Brief SummaryRATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
PURPOSE: This randomized phase III trial is studying two different methods of radiation and their side effects and comparing how well they work in treating endometrial and cervical cancer after surgery.
ConditionsCervical Cancer Endometrial Cancer Gastrointestinal Complications Perioperative/Postoperative Complications Radiation Toxicity Urinary Complications Urinary Tract Toxicity
Intervention TypeRadiation: Standard radiation therapy Radiation: intensity-modulated radiation therapy
Blinding MethodNone (Open Label)
Arms InterventionIntensity-Modulated Radiation Therapy - Experimental Standard Radiation Therapy - Active Comparator
PubMed (PMID)32073955 31104905 29989857
Collaborator(s)National Cancer Institute (NCI) NRG Oncology
Region(s)United States Canada Hong Kong Singapore
Age RangeMinimum Age: 18 Years Maximum Age: NA